MicroRNA: Siglec crosstalk in cancer progression

Denis Mustafov, Mohammed Saqif Ahmad, Antonio Serrano, Maria Braoudaki, Shoib Siddiqui

Research output: Contribution to journalReview articlepeer-review

23 Downloads (Pure)

Abstract

Aberrant Siglec expression in the tumour microenvironment has been implicated in tumour malignancies and can impact tumour behaviour and patient survival. Further to this, engagement with sialoglycans induces masked antigen recognition and promotes immune evasion, highlighting deregulated immune function. This necessitates the elucidation of their expression profiles in tumour progression. MicroRNAs (miRNAs) mediated targeting represents a novel approach to further elucidate Siglec potential and clinical relevance. Although miRNA activity in Siglec expression remains limited, we highlight current literature detailing miRNA:Siglec interactions within the tumour landscape and provide insights for possible diagnostic and therapeutic strategies in targeting the Siglec/sialic acid axis.
Original languageEnglish
Article number, August 2024, 102502
Pages (from-to)1-!0
Number of pages10
JournalCurrent Opinion in Chemical Biology
Volume81
Early online date18 Jul 2024
DOIs
Publication statusPublished - 30 Aug 2024

Fingerprint

Dive into the research topics of 'MicroRNA: Siglec crosstalk in cancer progression'. Together they form a unique fingerprint.

Cite this